Teleflex Announces Positive Data Showing that the UroLift® System Effectively Relieves Enlarged Prostate Symptoms While Preserving Patients’ Sexual Function

Teleflex
Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged Prostate

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced that data from two analyses of the UroLift® System were presented at the American Urological Association (AUA) 2020 Virtual Science event.

This new multimedia reinvention of the AUA 2020 poster and podium sessions was designed to connect and educate participants who are unable to gather as a result of the COVID-19 pandemic. Results from the analyses highlight the effectiveness of the minimally invasive treatment for benign prostatic hyperplasia (BPH) in preserving sexual function* and in a real-world setting.

“The UroLift System is an accepted standard of care treatment that provides rapid relief and recovery for men suffering from the burdensome symptoms of BPH,” said Dave Amerson, president of Teleflex Interventional Urology business unit. “Results from these analyses further support the use of this minimally invasive approach in the real-world as an alternative to BPH medications that often have unpleasant sexual side effects. The UroLift System allows many men to discontinue BPH medication and maintain – or even improve – their sexual function.”

The UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*1-5

Results from a meta-analysis of patients’ sexual function following treatment with the UroLift System versus medical therapy were presented by Claus Roehrborn, M.D., University of Texas Southwestern Medical Center.

The analysis compared sexual function outcomes in 849 sexually active men from the MTOPS (Medical Therapy of Prostatic Symptoms) study who received daily treatment with an alpha blocker, 5-alpha-reductase inhibitor, either alone or in combination and 190 men from combined clinical studies of the UroLift System (L.I.F.T. pivotal trial; L.I.F.T. Crossover study; MedLift study) at 12, 24, 36 and 48 months.

READ:  Genesis HealthCare Reports First Quarter 2020 Results; Provides COVID-19 Update

Results from the analysis showed that patients treated with the UroLift System experienced significant improvements in ejaculatory function and erectile function at 12 and 24-months post-treatment.

Patients also reported significant improvement in overall sexual satisfaction through 48 months post-treatment. In contrast, none of the medical therapies significantly improved patients’ erectile or ejaculatory function at any timepoint, and some therapies significantly reduced function. Patients taking finasteride reported a significant reduction in erectile function at 48 months, and patients that received a combination drug therapy experienced a significant reduction in ejaculatory function at 12 and 24 months.

The analysis revealed the UroLift System treatment was superior to finasteride and combination drug therapy at preserving erectile function at 12 and 24 months. Additionally, the UroLift System significantly outperformed all three medical therapies across all timepoints at preserving patients’ ejaculatory function. Only patients who received the UroLift System reported significant improvement in overall satisfaction in sexual life.

“Although not a head-to-head comparison, these results indicate that patients treated with the UroLift System achieved better outcomes in sexual function than men who received medical therapy,” said Dr. Roehrborn. “The UroLift System is a minimally invasive option for patients that may allow them to get off BPH medications and avoid sexual dysfunction. This is in line with the AUA clinical guidelines, recommending that patients be counseled about the sexual side effects of any BPH intervention.”

READ:  New Micro-Measurements Bridge Completion Modules (BCM) Improve Quality of Strain Measurements for Broad Range of Applications

To assess the UroLift System performance in a real-world setting compared to experience in controlled settings, an analysis compared patient outcomes from the large Real World Retrospective (RWR) study to those found in the L.I.F.T. pivotal trial and P.U.L.S.A.R. urinary retention trial, which studied catheter dependent BPH patients.

Results from the analysis were presented by Gregg Eure, M.D., urologist at Urology of Virginia. The RWR study gathered data from 3,226 patients that were treated with the UroLift System across 22 international sites. For the analysis, patients from the real-world study were divided into non-urinary retention and urinary retention groups.

Results from the analysis showed patients from all groups experienced similar absolute International Prostate Symptom Score (IPSS) scores at all timepoints following treatment with the UroLift System.

Analyses also revealed equivalent safety profiles among non-urinary retention and urinary retention patient groups from the real-world study when compared to corresponding groups in controlled studies. Finally, the results indicated that the majority of retention patients became catheter independent at the end of the studies – 84% in the RWR study and 73% in the P.U.L.S.A.R study.

READ:  Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

“These findings demonstrate that patients treated with the UroLift System in a real-world setting experience consistent symptom response, safety, and overall patient experience to those treated in a controlled setting,” said Dr. Eure. “Clinicians should be encouraged not only by the consistency of the real-world results to those seen in clinical studies, but also by the positive outcomes found among BPH patients with urinary retention who are often excluded from clinical studies but are seen in a real-world clinic setting.”

1. Roehrborn, J Urology 2013 LIFT Study
2. AUA BPH Guidelines 2003, 2010, 2018
3. Naspro, Eur Urol 2009
4. Montorsi, J Urol 2008
5. McVary, J Sex Med 2016
6. Shore, Can J Urol 2014 Local Study
7. Speakman et al. 2014 BJUI International
* No instances of new, sustained erectile or ejaculatory dysfunction
**Management estimate based on product sales and average units per procedure
Dr. Claus Roehrborn and Dr. Gregg Eure are paid consultants of NeoTract | Teleflex Interventional Urology.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee

Leave a Reply

avatar
  Subscribe  
Notify of